Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Hematology, Oncology and Stem Cell Therapy. 2017; 10 (1): 1-7
em Inglês | IMEMR | ID: emr-186589

RESUMO

Acute myeloid leukemia [AML] is defined as leukemic blast reproduction in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical specifications and results. t[8;21][q22;q22] and inv[16][p13;q22] form core binding factor- AML [CBF-AML]. c-kit mutation activation occurs in 12.8-46.1% of adults with CBF leukemia. These mutations occur in 20-25% of t[8;21] and 30% of inv[16] cases


Methods: In this systematic review, we searched different databases, including PubMed, Scopus, and Embase. Selected articles were measured based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, articles relevant to the subject of this review were retrieved in full text. Twenty-two articles matched the inclusion criteria and were selected for this review


Results: In this study, c-kit mutations were associated with poor prognosis in AML patients with t[8;21] and inv[16]. In addition, these mutations had better prognostic effects on AML patients with inv[16] compared with those with t[8;21]


Conclusion: According to the results of this study, c-kit mutations have intense, harmful effects on the relapse and white blood cell increase in CBF-AML adults. However, these mutations have no significant prognostic effects on patients

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA